Iterum Therapeutics plc
ITRM51
$1.81arrow_drop_up2.25%$0.04
Penny Stock
ITRM51
$1.81
arrow_drop_up2.25%Performance History
| Key Stats | |
|---|---|
| Open | $1.80 |
| Prev. Close | $1.77 |
| EPS | -1.76 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $49.80M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.71 | 1.95 |
| 52 Week Range | 0.62 | 2.50 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -1.76 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Iterum Therapeutics plc (ITRM)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Corey N. Fishman
- Headquarters
- Dublin
- Employees
- 14
- Exchange
- NASDAQ
Keep an eye on Iterum Therapeutics plc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Iterum Therapeutics plc's (ITRM) price per share?
The current price per share for Iterum Therapeutics plc (ITRM) is $1.81. The stock has seen a price change of $0.04 recently, indicating a 2.26% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Iterum Therapeutics plc (ITRM)?
For Iterum Therapeutics plc (ITRM), the 52-week high is $2.5, which is 38.12% from the current price. The 52-week low is $0.62, the current price is 191% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Iterum Therapeutics plc (ITRM) a growth stock?
Iterum Therapeutics plc (ITRM) has shown an average price growth of -4.13% over the past three years. It has received a score of 33 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Iterum Therapeutics plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Iterum Therapeutics plc (ITRM) stock price performance year to date (YTD)?
As of the latest data, Iterum Therapeutics plc (ITRM) has a year-to-date price change of -8.35%. Over the past month, the stock has experienced a price change of 67.59%. Over the last three months, the change has been 49.59%. Over the past six months, the figure is 27.46%. Looking at a longer horizon, the five-year price change stands at -93.78%.
help
Is Iterum Therapeutics plc (ITRM) a profitable company?
Iterum Therapeutics plc (ITRM) has a net income of -$38.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$47.47M. Furthermore, the EBITDA is -$37.36M.
help
What is the market capitalization of Iterum Therapeutics plc (ITRM)?
Iterum Therapeutics plc (ITRM) has a market capitalization of $49.8M. The average daily trading volume is 1.78, indicating the stock's liquidity and investor engagement.
News
ITERUM THERAPEUTICS
ORLYNVAH
FDA APPROVAL
UNCOMPLICATED URINARY TRACT INFECTIONS
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
ITERUM THERAPEUTICS
MAXIM HEALTHCARE
ANTIBIOTICS
MULTI-DRUG RESISTANT INFECTIONS
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
HEALTH
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
HEALTH
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
EARNINGS RELEASES AND OPERATING RESULTS
Iterum Therapeutics Reports First Quarter 2024 Financial Results
PRODUCT / SERVICES ANNOUNCEMENT
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem